CRP and cancer: Consider holding ICI therapy and other potential nephrotoxins (PPI, NSAIDs, other cancer drugs) and after conservative management (e.g., IV fluids) reevaluate within one week; if available biomarkers (i.e., CRP and uRBP/Cr) and both are WNL** and clinical evaluation has low probability for ICI-AKI, consider resuming ICI therapy if creatinine improved back or close to baseline. If kidney function is not improved, manages as AKI stage 2/3.